Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Delayed Quote INR

Colinz Laboratories Limited (COLINZ.BO)

Compare
53.00
+2.52
+(4.99%)
At close: 1:24:06 PM GMT+5:30
Loading Chart for COLINZ.BO
  • Previous Close 50.48
  • Open 53.00
  • Bid 53.00 x --
  • Ask --
  • Day's Range 53.00 - 53.00
  • 52 Week Range 42.00 - 88.70
  • Volume 431
  • Avg. Volume 1,526
  • Market Cap (intraday) 133.512M
  • Beta (5Y Monthly) 0.32
  • PE Ratio (TTM) 27.75
  • EPS (TTM) 1.91
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, and creams, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, and pegylated liposome doxorubicin, etc.; antiritrovirals, including lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, and vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. Further, it provides nutraceuticals, including spirulina tabs/caps, spirulina with vitamins and minerals, omega 3 fatty acids caps in softgel, codliver oil with vitamin caps in soft gel, amino acids tabs/caps, l-arginine with proantocyanidin granules, and hair growth formulations, etc., as well as collagen, glucosamine, and chondroitin tabs. Colinz Laboratories Limited was incorporated in 1986 and is based in Mumbai, India.

www.colinz.com

69

Full Time Employees

March 31

Fiscal Year Ends

Recent News: COLINZ.BO

View More

Performance Overview: COLINZ.BO

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

COLINZ.BO
24.03%
S&P BSE SENSEX (^BSESN)
1.40%

1-Year Return

COLINZ.BO
22.42%
S&P BSE SENSEX (^BSESN)
5.62%

3-Year Return

COLINZ.BO
22.42%
S&P BSE SENSEX (^BSESN)
32.06%

5-Year Return

COLINZ.BO
22.42%
S&P BSE SENSEX (^BSESN)
151.76%

Compare To: COLINZ.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: COLINZ.BO

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    127.16M

  • Enterprise Value

    54.87M

  • Trailing P/E

    26.43

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.90

  • Price/Book (mrq)

    1.36

  • Enterprise Value/Revenue

    0.82

  • Enterprise Value/EBITDA

    6.45

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.19%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    67.06M

  • Net Income Avi to Common (ttm)

    4.82M

  • Diluted EPS (ttm)

    1.91

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    80.41M

  • Total Debt/Equity (mrq)

    8.68%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: COLINZ.BO

View More

Company Insights: COLINZ.BO

Research Reports: COLINZ.BO

View More

People Also Watch